MX2019000415A - Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. - Google Patents
Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.Info
- Publication number
- MX2019000415A MX2019000415A MX2019000415A MX2019000415A MX2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A
- Authority
- MX
- Mexico
- Prior art keywords
- dna vaccine
- cancer immunotherapy
- production
- present
- transformed cell
- Prior art date
Links
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 108010041986 DNA Vaccines Proteins 0.000 abstract 2
- 229940021995 DNA vaccine Drugs 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un procedimiento de producción de una vacuna de ADN para inmunoterapia del cáncer que comprende al menos las etapas de (a) transformación de una cepa atenuada de Salmonella con al menos una molécula de ADN que comprende al menos un casete de expresión que codifica al menos un antígeno o al menos un fragmento del mismo; (b) caracterización de al menos un clon celular transformado obtenido en la etapa (a); y (c) selección de al menos uno de los clones celulares transformados caracterizado en la etapa (b) y caracterización adicional de dicho al menos un clon celular trasformado seleccionado. La presente invención se refiere adicionalmente a una vacuna de ADN que se puede obtener por el procedimiento de acuerdo con la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000415A true MX2019000415A (es) | 2019-03-28 |
Family
ID=56418345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000415A MX2019000415A (es) | 2016-07-13 | 2017-07-12 | Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (es) |
| EP (1) | EP3484503A1 (es) |
| JP (2) | JP7098599B2 (es) |
| KR (2) | KR20190027834A (es) |
| CN (1) | CN109475614A (es) |
| AU (1) | AU2017295004B2 (es) |
| BR (1) | BR112019000657A2 (es) |
| CA (1) | CA3028549A1 (es) |
| IL (1) | IL263568A (es) |
| MX (1) | MX2019000415A (es) |
| RU (1) | RU2019100079A (es) |
| SG (1) | SG11201811258UA (es) |
| WO (1) | WO2018011289A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190117603A (ko) | 2017-02-17 | 2019-10-16 | 백심 아게 | 신규 vegfr-2 표적화 면역요법상 접근법 |
| CA3069523A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| KR102869944B1 (ko) | 2018-07-11 | 2025-10-15 | 액팀 테라퓨틱스, 인코퍼레이티드 | 조작된 면역자극성 박테리아 균주 및 이의 용도 |
| US20210213121A1 (en) * | 2018-09-05 | 2021-07-15 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| WO2021144254A1 (en) | 2020-01-13 | 2021-07-22 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| JPWO2024005122A1 (es) * | 2022-06-30 | 2024-01-04 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2670745C9 (ru) * | 2011-05-24 | 2018-12-13 | Бионтех Рна Фармасьютикалс Гмбх | Индивидуализированные противоопухолевые вакцины |
| CA2853656C (en) * | 2011-12-22 | 2020-12-29 | Vaximm Ag | Method of producing high yield attenuated salmonella strains |
| BR112014033046A2 (pt) * | 2012-07-05 | 2017-06-27 | Vaximm Ag | linhagem mutante atenuada de salmonella typhi, vacina de dna e vacina de dna vxm01 |
| EP2988762B1 (en) * | 2013-04-25 | 2018-06-06 | Vaximm AG | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
| EP3082850B1 (en) * | 2013-12-18 | 2019-08-28 | Vaximm GmbH | Msln targeting dna vaccine for cancer immunotherapy |
| CN106456724A (zh) * | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
-
2017
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/ru not_active Application Discontinuation
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/zh active Pending
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en not_active Ceased
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/ko not_active Ceased
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/ko not_active Ceased
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/ja active Active
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/es unknown
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/pt not_active Application Discontinuation
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018011289A1 (en) | 2018-01-18 |
| IL263568A (en) | 2019-01-31 |
| US10821163B2 (en) | 2020-11-03 |
| EP3484503A1 (en) | 2019-05-22 |
| CA3028549A1 (en) | 2018-01-18 |
| AU2017295004A1 (en) | 2019-01-03 |
| KR20190027834A (ko) | 2019-03-15 |
| CN109475614A (zh) | 2019-03-15 |
| US20190183996A1 (en) | 2019-06-20 |
| US20220072112A1 (en) | 2022-03-10 |
| AU2017295004B2 (en) | 2020-08-13 |
| SG11201811258UA (en) | 2019-01-30 |
| US11590215B2 (en) | 2023-02-28 |
| JP2019521154A (ja) | 2019-07-25 |
| BR112019000657A2 (pt) | 2019-04-24 |
| KR20230079514A (ko) | 2023-06-07 |
| RU2019100079A (ru) | 2020-08-13 |
| JP2022097591A (ja) | 2022-06-30 |
| JP7098599B2 (ja) | 2022-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000415A (es) | Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. | |
| PH12020550214A1 (en) | Antibodies specific to cd47 and pd-l1 | |
| MX381241B (es) | Composición de células t para usarse en el tratamiento del cáncer. | |
| PH12018500634A1 (en) | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules | |
| SG11202010603TA (en) | Method for producing acrylic rubber, and acrylic rubber obtained by said production method | |
| MX2017006571A (es) | Moleculas de union a antigeno biespecificas activadoras de celulas t. | |
| MY179611A (en) | Bispecific t cell activating antigen binding molecules | |
| PH12015501906A1 (en) | Strain having enhanced l-valine productivity and l-valine production method using the same | |
| PH12020550952A1 (en) | Antibodies binding to hla-a2/wt1 | |
| MX2015009942A (es) | Sintesis de 1,1,2,3-tetracloropropeno. | |
| PH12019502274A1 (en) | Antibodies binding to steap-1 | |
| MY190659A (en) | Method for producing biohydrocarbons | |
| MY183219A (en) | Transformant for expressing cis-prenyltransferase and nogo b receptor | |
| MX2020003508A (es) | Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende. | |
| MX2019008241A (es) | Un enlazador polipeptídico para preparar anticuerpos multispecíficos. | |
| WO2019227106A9 (en) | Tumor-specific neoantigens and methods of using the same | |
| MX2019000326A (es) | Estera de fibra de carbono aleatoria y material compuesto de fibra de carbono. | |
| PH12017500722A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| MX2019012882A (es) | Cepa de microbacterium y metodo para producir psicosa utilizando la misma. | |
| EA201791423A1 (ru) | Способ получения белка | |
| SA517390305B1 (ar) | أنظمة وطرق متعلقة بإنتاج الأوليفين | |
| MY208508A (en) | Nasal hepatitis b vaccine composition and method for producing same | |
| MY189781A (en) | Method for preparing polythiols | |
| MY188494A (en) | High-growth enterovirus 71 strains and vaccines | |
| MY177218A (en) | Method for producing specific ?,?-unsaturated aldehydes by rearrangement process |